Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Anemia
Interventions: epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 31
States / cities: Covina, California • Los Alamitos, California • Los Angeles, California + 23 more

Conditions: Pancreatic Cancer
Interventions: Masitinib, Placebo, Gemcitabine; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Norwich, Connecticut • Orlando, Florida • Atlanta, Georgia + 9 more

Conditions: Hallux Valgus
Interventions: TLC590, Naropin®, Normal Saline, Bupivacaine; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: Subcutaneous Fat
Interventions: CBL-514 Injection, 0.9 % sodium chloride; Drug
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 50
States / cities: Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more

Conditions: Pain, Chronic, Pain Acute
Interventions: Real Transcranial Magnetic Stimulation, Sham Transcranial Magnetic Stimulation; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Anxiety Disorders
Interventions: Individual cognitive behavioral therapy (ICBT), Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT), Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 8 Years to 11 Years
Enrollment: 341 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: mibefradil, Placebo; Drug · Other
Lead sponsor: Cavion, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Renal Cell Carcinoma, Ovarian Tumor
Interventions: DS-6000a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Lake Mary, Florida + 2 more

Conditions: Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
Interventions: Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mantle Cell Lymphoma (MCL)
Interventions: Copanlisib, Ibrutinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Chronic Hepatitis C
Interventions: GS-5816; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Presbyopia
Interventions: LD127025 MF, Air Optix Aqua MF; Device
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Tourette Syndrome, Tic Disorders
Interventions: Habit reversal therapy, Supportive therapy; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: New Haven, Connecticut • Boston, Massachusetts • San Antonio, Texas

Conditions: Patent Ductus Arteriosus
Interventions: Early ibuprofen, Late ibuprofen expectant group (placebo); Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 1 Day to 14 Days
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Typhoid Fever
Interventions: CVD 909, Placebo, Vi Polysaccharide; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cervical Spine Degeneration, ACDF Surgery
Interventions: Early PT, Delayed PT; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Honolulu, Hawaii • Nashville, Tennessee • Fort Sam Houston, Texas + 1 more

Conditions: Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
Interventions: Niraparib, Irinotecan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atrial Fibrillation
Interventions: Open Concomitant Surgical Ablation Procedures, Hybrid (Convergent) Ablation Procedures, AtriCure Hybrid Totally Thoracoscopic Ablation Procedures, AtriCure LAA Exclusion Procedures; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 26
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Catheters, Indwelling
Interventions: Alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sedentary Lifestyle
Interventions: eHealth for Sedentary Behavior; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma
Interventions: Canfosfamide HCl for injection; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

RTMS for Treatment of Pain and Craving

Cognitive Behavioral Therapy With Parental Involvement for Treating Children With Anxiety Disorders

Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens

Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder

Timing of PDA Closure and Respiratory Outcome in Premature Infants

CVD 909 Vi Prime Boost Study

Function After Anterior Cervical Discectomy and Fusion Surgery: Timing of Physical Therapy

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Tracking Results of Ablations to Combat AF Registry Generation 2

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma